Nursing Considerations for Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma: Experience with Teclistamab from the MajesTEC-1 Study
Donna Catamero(Mount Sinai Health System), Sandy Kruyswijk(Amsterdam University Medical Centers), Rachel Kobos(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Margaret Doyle(Janssen (Ireland)), Jessica Fowler(Janssen (United States)), Patricia Blázquez Benito(Universidad de Salamanca), Samantha Shenoy(University of California, San Francisco)
Cited by 3
Related Papers
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
|Journal of Clinical Oncology|2022|647
Cutting Edge: The Transcription Factor Eomesodermin Enables CD8+ T Cells To Compete for the Memory Cell Niche
|The Journal of Immunology|2010|417